Veritas Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 19-12-2024
- Paid Up Capital ₹ 2.50 M
as on 19-12-2024
- Company Age 19 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.38 Cr
as on 19-12-2024
- Revenue -71.54%
(FY 2018)
- Profit -39.13%
(FY 2018)
- Ebitda -46.56%
(FY 2018)
- Net Worth 33.14%
(FY 2018)
- Total Assets 48.85%
(FY 2018)
About Veritas Life Sciences
The Corporate was formerly known as Avis Life Sciences Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 2.50 M.
The company currently has active open charges totaling ₹1.38 Cr.
Anil Mediratta, Amit Mediratta, Mohit Arora, and One other member serve as directors at the Company.
- CIN/LLPIN
U24232DL2005PLC141722
- Company No.
141722
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
14 Oct 2005
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Veritas Life Sciences?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anil Mediratta  | Managing Director | 14-Oct-2005 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Mohit Arora | Director | 01-Dec-2016 | Current |
| Amit Mediratta | Director | 14-Oct-2005 | Current |
| Kishor Jha | Director | 01-Dec-2021 | Current |
Financial Performance of Veritas Life Sciences.
Veritas Life Sciences Limited, for the financial year ended 2018, experienced significant reduction in revenue, with a 71.54% decrease. The company also saw a substantial fall in profitability, with a 39.13% decrease in profit. The company's net worth Soared by an impressive increase of 33.14%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Veritas Life Sciences?
In 2018, Veritas Life Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Pharmasys Private LimitedActive 5 years 7 months
Anil Mediratta and Amit Mediratta are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Indian Bank Creation Date: 10 Apr 2024 | ₹1.38 Cr | Open |
How Many Employees Work at Veritas Life Sciences?
Veritas Life Sciences has a workforce of 36 employees as of Apr 01, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Veritas Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Veritas Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
